- Total fourth quarter revenue of $474M, including Screening revenue of $278M, Precision Oncology revenue of $149M, and COVID-19 testing revenue of $47M
- Total 2021 revenue, excluding COVID-19 testing, increased 29% compared to 2020, including 30% increase in Screening revenue and 28% increase in Precision Oncology revenue
- Screening revenue growth driven by Cologuard rescreens, Cologuard use in 45-49 age group, expansion of primary care sales team, and increased in-person sales calls
That's a real company and why their share price is $73 usd
Nailoser and friends you put your money in the wrong one
![Stream Too Late by NyKeeM | Listen online for free on SoundCloud](https://i1.sndcdn.com/artworks-000191109401-nwydbo-t500x500.jpg)